 MENLO PARK, Calif., June 22, 2021 GLOBE NEWSWIRE -- Corcept Therapeutics Incorporated NASDAQ: CORT, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced preliminary results from its Phase 3 RELIANT trial of relacorilant combined with nab-paclitaxel in patients with metastatic pancreatic cancer. 